Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach

被引:17
作者
Li, Yuehong [1 ]
Lou, Lei [1 ]
Wang, Yuan [1 ]
Cui, Jinfeng [1 ]
Yan, Xia [2 ]
Xue, Liying [2 ]
机构
[1] Hebei Med Univ, Hosp 2, Dept Pathol, Shijiazhuang, Peoples R China
[2] Hebei Med Univ, Pathol Lab, Shijiazhuang, Peoples R China
基金
中国国家自然科学基金;
关键词
Pim-3; p-p27; c-Myc; Gastric cancer; Cardiac adenocarcinoma; Distal adenocarcinoma; KINASE INHIBITOR P27(KIP1); CELL-CYCLE PROGRESSION; CANCER; P27; PROLIFERATION; CARCINOMA; PHOSPHORYLATION; SEQUESTRATION; PROTOONCOGENE; LOCALIZATION;
D O I
10.1007/s13277-014-1664-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastric cardia adenocarcinoma (GCA) is distinct from adenocarcinoma of the distal stomach because of its different etiological factors, tumor characteristics, and biological behavior. However, its pathogenesis is not fully understood. The purpose of this study is to characterize the role of Pim-3, c-Myc, and p-p27 in the tumorigenesis and progression of different sites of gastric adenocarcinoma by determining its pathogenetic significance. The expression of Pim-3, c-Myc, and p-p27 proteins was evaluated by immunohistochemistry in 140 resection specimens of gastric adenocarcinomas (78 GCAs , 62 DGAs and 20 normal gastric tissues). The level of expression of Pim-3, c-Myc, and p-p27 and the co-expression of all three markers (Pim-3+/c-Myc+/p-p27+) in GCA were significantly lower than that in DGA tumors (P < 0.05). Detailed analysis of the immunoreactivity patterns showed that in DGA, Pim-3 immunoreactivity was associated significantly with poor tumor differentiation, advanced tumor stage, and presence of lymph node metastasis. In addition, c-Myc overexpression correlated with tumor stage and lymph node metastasis, and positive p-p27 expression correlated with poor differentiation and tumor stage. The phenotype of Pim-3(+)/c-Myc(+)/p-p27(+) co-expression was closely correlated with tumor stage and lymph node metastasis (P < 0.05). In contrast, GCA only demonstrated a close correlation of Pim-3 overexpression with poor tumor differentiation and tumor stage (P < 0.05). Our results demonstrate the presence of different expression patterns of Pim-3, c-Myc, p-p27, and Pim-3(+)/c-Myc(+)/p-p27(+) and their clinicopathologic significance in GCA and DGA tumors. Our results add support to the notion that distinct molecular mechanisms may be involved in the development and progression of adenocarcinomas from the gastric cardia and distal portion of stomach.
引用
收藏
页码:5029 / 5036
页数:8
相关论文
共 51 条
[1]   Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc [J].
Allen, JD ;
Verhoeven, E ;
Domen, J ;
vanderValk, M ;
Berns, A .
ONCOGENE, 1997, 15 (10) :1133-1141
[2]  
[Anonymous], 2008, SHIJIE HUAREN XIAOHU, V16, P3515
[3]   The Pim protein kinases regulate energy metabolism and cell growth [J].
Beharry, Zanna ;
Mahajan, Sandeep ;
Zemskova, Marina ;
Lin, Ying-Wei ;
Tholanikunnel, Baby G. ;
Xia, Zuping ;
Smith, Charles D. ;
Kraft, Andrew S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (02) :528-533
[4]   Deregulated degradation of the cdk inhibitor p27 and malignant transformation [J].
Bloom, J ;
Pagano, M .
SEMINARS IN CANCER BIOLOGY, 2003, 13 (01) :41-47
[5]   Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 [J].
Bouchard, C ;
Thieke, K ;
Maier, A ;
Saffrich, R ;
Hanley-Hyde, J ;
Ansorge, W ;
Reed, S ;
Sicinski, P ;
Bartek, J ;
Eilers, M .
EMBO JOURNAL, 1999, 18 (19) :5321-5333
[6]   PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers [J].
Brault, Laurent ;
Gasser, Christelle ;
Bracher, Franz ;
Huber, Kilian ;
Knapp, Stefan ;
Schwaller, Juerg .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (06) :1004-1015
[7]   Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer [J].
Catzavelos, C ;
Bhatacharya, N ;
Ung, YC ;
Wilson, JA ;
Roncari, L ;
Sandhu, C ;
Shaw, P ;
Yeger, H ;
MoravaProtzner, I ;
Kapusta, L ;
Franssen, E ;
Pritchard, KI ;
Slingerland, JM .
NATURE MEDICINE, 1997, 3 (02) :227-230
[8]  
Esposito V, 1997, CANCER RES, V57, P3381
[9]  
Flejou Jean-Francois, 2011, Ann Pathol, V31, pS27, DOI 10.1016/j.annpat.2011.08.001
[10]  
Forshell LP, 2011, ONCOTARGET, V2, P448